Surfaxin FDA Approval History
FDA Approved: Yes (Discontinued) (First approved March 6, 2012)
Brand name: Surfaxin
Generic name: lucinactant
Dosage form: Intratracheal Suspension
Company: Discovery Laboratories, Inc.
Treatment for: Respiratory Distress Syndrome
Marketing Status: Discontinued
Surfaxin (lucinactant) is a synthetic, peptide-containing surfactant indicated for the prevention of respiratory distress syndrome (RDS) in premature infants.
Development timeline for Surfaxin
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.